Sirtex Medical (ASX:SRX) is looking for new leadership after terminating the employment of CEO Mr Gilman Wong.
In a statement, the makers of SIR-Spheres Y-90 resin microspheres for cancer, said the decision was made after an investigation led by the company’s legal advisers, Watson Mangioni.
The investigation looked at Mr Wong's trading of shares in Sirtex in October 2016.
According to the company, Mr Nigel Lange has been appointed acting CEO. He is the current Chief Operating Officer of Sirtex, with over 14 years direct experience in the core SIR-Spheres Y-90 resin microspheres business.
“I look forward to delivering on our strategies, to maximise the potential of our SIR-Spheres microspheres technology, and to reinstate value to our shareholders,” he said.
Sirtex said it will conduct a thorough executive search and recruitment process to fill the position of CEO and intends to appoint an executive search firm to oversee the process and global search.
Separately, it announced the appointment of Anthony Dixon as CEO, EMEA, with immediate effect.
Mr Lange said: “Tony has been with Sirtex Medical Europe for nine years and has a strong track record in oncology and the medical devices sector, having served as National Sales Manager UK, Director of Marketing and more recently the Vice President of Marketing EMEA.”
He added that he expects the appointment of a CEO, APAC, to be made prior to the end of January.